Cygenta, a cell and gene therapy (CGT) focused Contract Development and Manufacturing Organization (CDMO) based in Beijing, has announced a strategic partnership with Russia-based IZVARINO Pharma Limited Liability Company. The collaboration aims to enhance the development and manufacturing capabilities for both companies, with a focus on advancing therapies in the CGT space.
Scope of Services Under the Agreement
Under the terms of the agreement, Cygenta will provide IZVARINO with a comprehensive suite of one-stop CDMO services. These services will encompass plasmid and lentiviral vector production, which are critical components in the development of gene therapies. Additionally, Cygenta will offer CAR-T product process optimization, analysis method development, and supply chain management. The partnership, while not disclosing financial details, signifies a significant step in bolstering the capabilities of both organizations.
Strengthening the Global CGT Ecosystem
This partnership between Cygenta and IZVARINO Pharma underscores the growing global demand for specialized CDMO services in the cell and gene therapy sector. By leveraging Cygenta’s expertise and capabilities, IZVARINO Pharma can accelerate its product development timelines and improve the efficiency of its manufacturing processes.-Fineline Info & Tech
